Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases

Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nusinersen (Spinraza)</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Inotersen (Tegsedi)</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Patisiran (Onpattro)</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Golodirsen (Vyondys 53)</td>
<td>DMD</td>
</tr>
<tr>
<td class="label">Viltolarsen (Viltepso)</td>
<td>DMD</td>
</tr>
<tr>
<td class="label">Tofersen (Qalsody)</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Phosphorothioate</td>
<td>Nuclease resistance, RNase H activity</td>
</tr>
<tr>
<td class="label">2'-O-methyl</td>
<td>Improved binding, reduced immunogenicity</td>
</tr>
<tr>
<td class="label">2'-O-methoxyethyl</td>
<td>Enhanced nuclease resistance</td>
</tr>
<tr>
<td class="label">Locked nucleic acid (LNA)</td>
<td>High-affinity binding</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate morpholino (PMO)</td>
<td>RNase H-independent</td>
</tr>
</table>

Overview

Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide (ASO) Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nusinersen (Spinraza)</td>
<td>SMN2</td>
</tr>
<tr>
<td class="label">Inotersen (Tegsedi)</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Patisiran (Onpattro)</td>
<td>TTR</td>
</tr>
<tr>
<td class="label">Golodirsen (Vyondys 53)</td>
<td>DMD</td>
</tr>
<tr>
<td class="label">Viltolarsen (Viltepso)</td>
<td>DMD</td>
</tr>
<tr>
<td class="label">Tofersen (Qalsody)</td>
<td>SOD1</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Phosphorothioate</td>
<td>Nuclease resistance, RNase H activity</td>
</tr>
<tr>
<td class="label">2'-O-methyl</td>
<td>Improved binding, reduced immunogenicity</td>
</tr>
<tr>
<td class="label">2'-O-methoxyethyl</td>
<td>Enhanced nuclease resistance</td>
</tr>
<tr>
<td class="label">Locked nucleic acid (LNA)</td>
<td>High-affinity binding</td>
</tr>
<tr>
<td class="label">Phosphorodiamidate morpholino (PMO)</td>
<td>RNase H-independent</td>
</tr>
</table>

Overview

Antisense Oligonucleotide (ASO) therapies represent a revolutionary approach to treating neurodegenerative diseases by directly targeting disease-causing genetic transcripts. ASOs are short, single-stranded DNA or RNA molecules that bind to specific mRNA sequences via Watson-Crick base pairing, thereby modulating protein expression through mechanisms including ribonuclease H (RNase H)-mediated mRNA degradation, splicing modification, or translational blocking. This precision medicine approach has shown remarkable success in neurological disorders and is being rapidly expanded to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). [@kordasner2024]

Mechanism of Action

Primary Mechanisms

RNase H-Mediated Degradation

• ASO binds to complementary mRNA
• RNase H recognizes DNA-RNA hybrid and cleaves the RNA strand
• Leads to reduced translation of the target protein
• Effective for reducing toxic protein expression

Splicing Modulation

• ASO binds to pre-mRNA splice sites or intronic/exonic regions
• Can exclude or include specific exons (exon skipping/inclusion)
• Useful for diseases caused by aberrant splicing
• Example: Nusinersen for spinal muscular atrophy

Translational Blocking

• ASO blocks ribosomal translation initiation or elongation
• Prevents protein synthesis without degrading mRNA
• Useful when partial reduction is desired

Delivery Methods

Intrathecal Delivery

• Direct injection into cerebrospinal fluid (CSF)
• Bypasses blood-brain barrier (BBB)
• Used for nusinersen (Spinraza), tofersen
• Requires lumbar puncture

Intravenous Delivery

• Conjugated or formulated ASOs cross BBB
• GalNAc conjugation targets liver (not CNS)
• Emerging CNS-targeted delivery systems
• Requires higher doses

Conjugate Approaches

• GalNAc: Targets hepatocytes (for peripheral diseases)
• CPPs: Cell-penetrating peptides
• Antibodies: Receptor-mediated endocytosis
• Aptamers: Targeted CNS delivery

Clinical Applications

FDA-Approved ASO Therapies

ASOs in Development for Neurodegenerative Diseases

Alzheimer's Disease (AD)

• Anti-[tau](/proteins/tau) ASOs: Multiple programs targeting [MAPT](/proteins/mapt-protein) mRNA
• Anti-APP ASOs: Reducing [amyloid precursor protein](/entities/app-protein)
• Anti-BACE1 ASOs: Blocking [beta-secretase](/entities/bace1)
• Splicing modulators: Targeting [APOE](/proteins/apoe-protein) isoforms

Parkinson's Disease (PD)

• LRRK2-targeting ASOs: Reducing mutant LRRK2 expression
• [Alpha-synuclein](/proteins/alpha-synuclein) ASOs: [ASO Therapy for PD](/therapeutics/aso-therapy-parkinsons) - targeting SNCA transcript
• GBA-modulating ASOs: For GBA-associated PD

Amyotrophic Lateral Sclerosis (ALS)

• [C9orf72](/entities/c9orf72) ASOs: Targeting hexanucleotide repeat transcripts
• FUS ASOs: Targeting FUS mutations
• ATXN2 ASOs: Targeting intermediate repeats
• [TDP-43](/proteins/tdp-43) modulators: For sporadic ALS

Huntington's Disease (HD)

• HTT-targeting ASOs: Reducing mutant [huntingtin](/proteins/huntingtin-protein) (multiple programs)
• Allele-selective ASOs: Targeting mutant only
• Non-allele-selective: Reducing both wild-type and mutant

Advantages of ASO Therapy

Precision Medicine

• Targeted: Directly targets disease-causing genes
• Personalizable: Can be designed for specific mutations
• Modulation: Dose-dependent protein reduction
• Reversible: Effects wear off if treatment stops

Biological Advantages

• [Blood-brain barrier](/entities/blood-brain-barrier): Can be delivered intrathecally
• Small molecules: Synthetic, scalable manufacture
• Long-lasting: Dosing every few months
• Combinable: Can be combined with other therapies

Challenges

• Delivery: CNS delivery remains challenging
• Safety: Off-target effects, hepatotoxicity
• Immunogenicity: Immune response to ASOs
• Cost: High development and treatment costs

Key Clinical Trials

Tofersen (BIIB067) - SOD1 ALS

• Phase III VALOR trial: Primary endpoint not met but open-label extension shows benefit
• Biomarker reduction: 60% reduction in SOD1 protein in CSF
• Clinical outcomes: Slower progression in early-treated patients

IONIS-HTTRx (Roche) - Huntington's Disease

• Phase I/II trial: First-in-human demonstration of HTT lowering
• Dose-dependent reduction: Up to 50% reduction in mutant [huntingtin](/genes/htt)
• Phase III in planning: GENERATION HD1

Anti-tau ASOs (Ionis/Biogen)

• Phase I/II: Safety and tolerability established
• Biomarker data: Dose-dependent reduction in total tau
• Phase III planned: For early AD

Manufacturing and Design

Chemical Modifications

Key Design Considerations

• Sequence selection: Computational and experimental validation
• Modification pattern: Balancing efficacy and toxicity
• Delivery system: Optimizing CNS penetration
• Dosing regimen: Balancing efficacy and safety

External Links

• [PubMed - GIP GLP-1 Dual Agonists Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=GIP+GLP-1+dual+agonist+neurodegeneration)
• [Tirzepatide Clinical Trials](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=tirzepatide)
• [ADA - Incretin Effects on Brain](https://diabetes.diabetesjournals.org/content/70/11/2553)
• [Nature - Incretins Neuroprotection](https://www.nature.com/articles/s41583-021-00426-2)
• [NIH - GLP-1 Receptor Agonists CNS](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276817/)

Background

The study of Antisense Oligonucleotide (Aso) Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Tofersen Treatment](/therapeutics/tofersen)
• [Nusinersen Treatment](/mechanisms/dopaminergic-neuron-vulnerability)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [SOD1 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [C9orf72 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [HTT Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [SNCA Gene](/diseases/snca-variants)
• [LRRK2 Gene](/genes/lrrk2)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)